INTELLIGENT BIO SOLUTIONS INC.
Close on Oct 19, 2026
- Market cap
- $3.83M
- P/E (TTM)
- –
- Dividend yield
- –
About Intelligent Bio Solutions
Surgical & Medical Instruments & Apparatus, SIC 3841
Intelligent Bio Solutions Inc. is a medical technology company that develops and supplies rapid, non-invasive screening and testing solutions. Its primary offering is the Intelligent Fingerprinting Platform, which features a proprietary drug screening system that analyzes sweat from fingerprints. The system consists of single-use, tamper-evident cartridges and a portable reader unit designed to screen for substances such as opiates, cocaine, methamphetamine, benzodiazepines, cannabis, methadone, and buprenorphine. The company also distributes wearable drug-detection sweat patches. Its customers primarily include organizations in safety-critical sectors, such as construction, manufacturing, engineering, mining, transportation, and logistics, along with judicial bodies and rehabilitation treatment providers.
The company operates globally, with sales predominantly concentrated in the United Kingdom, mainland Europe, and the Middle East, while pursuing distribution across Australia, New Zealand, and North America. It produces cartridges at a manufacturing facility in Cambridge, England, and maintains corporate headquarters in New York City.
Summary of the business section of Intelligent Bio Solutions's latest annual report, written by StockData.
Company profile
Company
- Legal name
- INTELLIGENT BIO SOLUTIONS INC.
- Founded
- 2016
- Headquarters
- New York, NY
- Address
- 135 W 41st St,, Floor 5 10036
- Phone
- (646) 790-5756
- Employees
- 14, Jun 30, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- UHY LLP, Melville, New York
Stock & identifiers
- Ticker
- INBS
- Exchange
- Nasdaq
- IPO date
- Dec 28, 2020
- Shares outstanding
- 3M, Aug 18, 2026
- Public float
- $11.71M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Feb 12, 2026; 1-for-10 reverse, Dec 16, 2025; 1-for-12 reverse, Feb 9, 2024; 1-for-12 reverse, Jan 29, 2024; 1-for-20 reverse, Feb 14, 2023; 1-for-20 reverse, Feb 10, 2023
- SEC CIK
- 1725430
- CUSIP
- 36151G709
- ISIN
- US36151G7097
- LEI
- 549300JIQ6MVR4PC5311
- EIN
- 82-1512711
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Harry Simeonidis | Chief Executive Officer | 34,540 |
| Spiro Kevin Sakiris | Chief Financial Officer | 35,892 |
| Steven Constantine Boyages | Director | 5,031 |
| Jonathan Scott Hurd | Director | 5,006 |
| Jason Isenberg | Director | 5,000 |
| Nicola Marion Fraser | Director | 5,000 |
Employees
Headcount reported in annual reports
“As of August 14, 2025, we have 14 full-time employees in Australia and 2 in the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 16, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 4, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 17, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 3, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 18, 2022 | Name change | Name changed from GBS Inc. to INTELLIGENT BIO SOLUTIONS INC. |
| Oct 11, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 23, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 28, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 22, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 19, 2019 | Name change | Name changed from Glucose Biosensor Systems (Greater China) Holdings, Inc. to GBS Inc. |